How many 8-K filings has Ideaya Biosciences, Inc. filed?

Ideaya Biosciences, Inc. (IDYA) has 28 8-K (Current Event Report) filings on record, spanning Jan 2024 to May 2026.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Ideaya Biosciences, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Ideaya Biosciences, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Ideaya Biosciences, Inc. (IDYA) — 8-K Filings

All 8-K filings from Ideaya Biosciences, Inc.. Browse 28 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (28)

8-K Filing — May 5, 2026
IDEAYA Biosciences Terminates Material Definitive Agreement — Dec 12, 2025 Risk: medium
IDEAYA Biosciences, Inc. announced on December 9, 2025, the termination of a material definitive agreement. The company, incorporated in Delaware, filed this 8-
8-K Filing — Dec 5, 2025
IDEAYA Biosciences Closes $175.1M Public Offering — Oct 20, 2025 Risk: medium
On October 17, 2025, IDEAYA Biosciences, Inc. announced the closing of its previously disclosed underwritten public offering. The company successfully sold appr
IDEAYA Biosciences Files 8-K — Sep 8, 2025 Risk: low
IDEAYA Biosciences, Inc. filed an 8-K on September 8, 2025, reporting an "Other Event" on September 7, 2025. The filing does not contain specific details about
IDEAYA Biosciences Enters Material Definitive Agreement — Sep 2, 2025 Risk: medium
IDEAYA Biosciences, Inc. entered into a material definitive agreement on August 29, 2025. The filing does not disclose specific details of the agreement, such a
IDEAYA Biosciences Appoints New Director, Adjusts Executive Pay — Jun 27, 2025 Risk: medium
IDEAYA Biosciences, Inc. announced on June 26, 2025, changes in its board of directors and executive compensation. Specifically, Dr. Paul R. Hastings was appoin
IDEAYA Biosciences Files 8-K on Shareholder Vote Matters — Jun 24, 2025 Risk: low
On June 24, 2025, IDEAYA Biosciences, Inc. filed an 8-K report indicating a submission of matters to a vote of security holders. The filing does not contain spe
IDEAYA Biosciences Announces Board and Compensation Changes — Apr 2, 2025 Risk: medium
IDEAYA Biosciences, Inc. announced on March 28, 2025, changes related to its board of directors and executive compensation. Specifically, the company reported t
IDEAYA Biosciences Files 8-K on Financials — Feb 13, 2025 Risk: low
On February 13, 2025, IDEAYA Biosciences, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, a
IDEAYA Biosciences Announces Board and Executive Changes — Feb 10, 2025 Risk: medium
IDEAYA Biosciences, Inc. announced on February 10, 2025, changes in its board of directors and executive compensation arrangements. The filing details the depar
IDEAYA Biosciences Enters Material Definitive Agreement — Dec 30, 2024 Risk: medium
On December 27, 2024, IDEAYA Biosciences, Inc. entered into a material definitive agreement. The filing also includes financial statements and exhibits related
IDEAYA Biosciences to be Acquired for $1.1 Billion — Oct 25, 2024 Risk: medium
IDEAYA Biosciences, Inc. announced on October 25, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of HealthCare Royalty Par
IDEAYA Biosciences Files 8-K — Oct 4, 2024 Risk: low
IDEAYA Biosciences, Inc. filed an 8-K on October 4, 2024, reporting other events and financial statements. The filing does not contain specific details about ne
IDEAYA Biosciences Files 8-K Report — Sep 23, 2024 Risk: low
On September 23, 2024, IDEAYA Biosciences, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financia
IDEAYA Biosciences Files 8-K for Operations Update — Aug 6, 2024 Risk: low
IDEAYA Biosciences, Inc. filed an 8-K on August 6, 2024, to report on its results of operations and financial condition, as well as to file financial statements
IDEAYA Biosciences Secures $150M Credit Facility — Jul 31, 2024 Risk: medium
On July 30, 2024, IDEAYA Biosciences, Inc. entered into a material definitive agreement, specifically a Second Amended and Restated Credit Agreement. This agree
IDEAYA Biosciences Closes $247M Public Offering — Jul 11, 2024 Risk: medium
On July 9, 2024, IDEAYA Biosciences, Inc. announced the closing of its previously disclosed underwritten public offering. The company successfully sold approxim
IDEAYA Biosciences to be Acquired for $1.1 Billion — Jul 9, 2024 Risk: low
IDEAYA Biosciences, Inc. announced on July 9, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of HealthCare Royalty Partner
IDEAYA Biosciences Appoints New Chief Medical Officer — Jul 8, 2024 Risk: medium
On July 8, 2024, IDEAYA Biosciences, Inc. announced the appointment of Dr. S. Mark Smith as Chief Medical Officer. Dr. Smith brings extensive experience in onco
IDEAYA Biosciences Appoints New CMO, Elects Directors — Jun 27, 2024 Risk: medium
IDEAYA Biosciences, Inc. announced on June 21, 2024, the appointment of Dr. S. Mark Albagli as Chief Medical Officer and the election of Dr. Albagli and Ms. Sar
IDEAYA Biosciences Files 8-K Update — Jun 3, 2024 Risk: low
On June 3, 2024, IDEAYA Biosciences, Inc. filed an 8-K report. The filing indicates that the company is providing an update on its clinical programs and busines
IDEAYA Biosciences Files 8-K on Shareholder Vote Matters — May 31, 2024 Risk: low
IDEAYA Biosciences, Inc. filed an 8-K on May 31, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific de
IDEAYA Biosciences Enters Material Definitive Agreement — Mar 12, 2024 Risk: medium
IDEAYA Biosciences, Inc. entered into a material definitive agreement on March 8, 2024. The filing does not disclose specific details of the agreement, such as
IDEAYA Biosciences Files Administrative 8-K; No New Material Info — Jan 23, 2024
IDEAYA Biosciences, Inc. filed an 8-K on January 23, 2024, reporting an 'Other Events' item from January 22, 2024. This filing primarily serves to update admini
IDEAYA Biosciences Reports Material Definitive Agreement; Details Undisclosed — Jan 19, 2024
IDEAYA Biosciences, Inc. filed an 8-K on January 19, 2024, to report an "Entry into a Material Definitive Agreement." While the filing confirms the agreement's
IDEAYA Biosciences Files 8-K on 'Other Event'; No New Material Info — Jan 16, 2024
IDEAYA Biosciences, Inc. filed an 8-K on January 12, 2024, to report an 'Other Event.' This filing primarily serves to update administrative details, such as co
IDEAYA Biosciences Files 8-K for 'Other Event' on Jan 4, 2024 — Jan 12, 2024
IDEAYA Biosciences, Inc. filed an 8-K on January 12, 2024, reporting an 'Other Event' that occurred on January 4, 2024. This filing primarily updates administra

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX